Hong Kong · Delayed Price · Currency is HKD Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Company Description
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of bio-pharmaceutical products in the People's Republic of China.
It offers genetic engineering platform drugs, including Trop2-SN38 ADC that is in Phase III clinical trials for Triple-negative breast cancer; CD30-DM1 antibody-drug conjugate (ADC), which have complected Phase I clinical trials for tumors; Trop2-BB05 ADC that is in Phase I clinical trial for tumors; DLL3-BB05 ADC, which is in phase I clinical trial for tumors; and HER2 ADC that is in phase I clinical study for tumors.
The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which has completed Phase IV clinical trial; and Aminolevulinic acid–CIN, which has completed Phase II clinical trials for cervical diseases infected by HPV; Aminolevulinic acid–AK, which is in phase II clinical trials for Actinic keratosis; Aminolevulinic acid–acne, which is in phase II clinical trials for Acne; Aminolevulinic acid–gliomas for surgical visualization of gliomas; Aminolevulinic acid–bladder for surgical visualization of bladder cancer; and Aminolevulinic acid–breast for surgical visualization of breast cancer.
In addition, it offers Osmotic pump technology platform drugs, which includes controlled-release carbidopa/levodopa Tablets which have complected phase II clinical trials for Early Parkinson’s disease; and Obeticholic acid for the treatment of hepatobiliary/autoimmune diseases.
Further, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software.
Additionally, the company engages in the technology development, transfer, consulting, and promotion activities.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. was founded in 1996 and is based in Shanghai, the People's Republic of China.
| Country | China |
| Founded | 1996 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 925 |
| CEO | Da Jun Zhao |
Contact Details
Address: Zhangjiang Hi-Tech Park Shanghai, 201210 China | |
| Phone | 86 21 5895 3355 |
| Website | fd-zj.com |
Stock Details
| Ticker Symbol | 1349 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000000W4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Da Jun Zhao | Co-Founder, GM and Executive Chairman |
| Xue Yan ACCA, CIA, CICPA, FCCA, HKICPA | Chief Financial Officer, Deputy GM, Company Secretary and Executive Director |
| Jun Li | Co-Founder and Deputy GM |
| Wen Zhang | Accounting Supervisor |
| Luo Chun Wang | Core Technical Personnel |
| Dai Qing Yu | Deputy General Manager |
| Yu Chen | Deputy General Manager |
| Xiaowen Li | Deputy General Manager |
| Lei Qin | Deputy General Manager |
| Jian Ping Jiang | Core Technical Personnel |